

## Special Issue

# Treatment Modalities for Non-small Cell Lung Cancer—A Clinical Survey

### Message from the Guest Editor

Lung cancer is one of the most aggressive types of cancer, with non-small-cell lung cancer being the most common histologic subtype of primary lung cancer. Despite continuous progress in surgery, chemotherapy, radiation therapy, and immune and targeted therapies, the prognosis of non-small-cell lung cancer patients still remains modest, especially those with advanced tumor disease. For this reason, this Special Issue of *Cancers* will highlight the different surgical and non-surgical treatment modalities available for non-small-cell lung cancer, focusing on the clinical aspect and related research activity. In this context, special attention will be paid to the current multimodal treatment options, to the impact of oncological immunology, and to the role of the tumor microenvironment in order to provide a comprehensive overview of this challenging topic.

### Guest Editor

Dr. Joerg Lindenmann

Division of Thoracic and Hyperbaric Surgery, Department of Surgery, Medical University of Graz, 8036 Graz, Austria

### Deadline for manuscript submissions

closed (14 September 2023)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/52216](https://mdpi.com/si/52216)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)